1 March 2024 in Circulation: Cardiovascular Interventions
OIon behalf of the CHIP-BCIS3 Investigators
on behalf of the CHIP-BCIS3 Investigators
+14
INTRODUCTION: Percutaneous coronary intervention for complex coronary disease is associated with a high risk of cardiogenic shock. This can cause harm and limit the quality of revascularization achieved, especially when left ventricular function is impaired at the outset. Elective percutaneous left ventricular unloading is increasingly used to mitigate adverse events in patients undergoing high-risk percutaneous coronary intervention, but this strategy has fiscal and clinical costs and is not supported by robust evidence. METHODS: CHIP-BCIS3 (Controlled Trial of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading) is a prospective, multicenter, open-label randomized controlled trial that aims to determine whether a strategy of elective percutaneous left ventricular unloading is superior to standard care (no planned mechanical circulatory support) in patients undergoing nonemergent high-risk percutaneous coronary intervention. Patients are eligible for recruitment if they have severe left ventricular systolic dysfunction, extensive coronary artery disease, and are due to undergo complex percutaneous coronary intervention (to the left main stem with calcium modification or to a chronic total occlusion with a retrograde approach). Cardiogenic shock and acute ST-segment–elevation myocardial infarction are exclusions. The primary outcome is a hierarchical composite of all-cause death, stroke, spontaneous myocardial infarction, cardiovascular hospitalization, and periprocedural myocardial infarction, analyzed using the win ratio. Secondary outcomes include completeness of revascularization, major bleeding, vascular complications, health economic analyses, and health-related quality of life. A sample size of 250 patients will have in excess of 80% power to detect a hazard ratio of 0.62 at a minimum of 12 months, assuming 150 patients experience an event across all follow-up. CONCLUSIONS: To date, 169 patients have been recruited from 21 National Health Service hospitals in the United Kingdom, with recruitment expected to complete in 2024. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05003817.
1 July 2025 in Circulation: Cardiovascular Interventions
BACKGROUND: Pressure-based physiological evaluation of coronary artery disease is well established, but its application is limited in left main coronary artery (LMCA) disease. Our aim was to investigate whether pressure-based indices are comparable in the left anterior descending (LAD) and left circumflex artery (LCx) branches of the LMCA, and if discordance is due to differences in microvascular function in these territories. METHODS: Simultaneous measurements of coronary pressure and flow were made in patients with (1) isolated LMCA disease and (2) unobstructed coronary arteries. Fractional flow reserve, instantaneous wave-free ratio, and microvascular resistance reserve values in the LAD were compared with those of the LCx. RESULTS: A total of 80 patients were enrolled (mean age 65±10 years, 56% male). In those with isolated LMCA disease, fractional flow reserve in the LAD was lower than in the LCx (0.74±0.11 versus 0.81±0.11; P <0.0001). Instantaneous wave-free ratio was also lower in the LAD (0.89 [0.76–0.92] versus 0.94 [0.88–0.97]; P <0.0001). The misclassification rates of functionally significant coronary disease, when these indices were measured in the LCx, were 21% for fractional flow reserve and 28% for instantaneous wave-free ratio. Microvascular resistance reserve was higher in the LAD than the LCx, in cohorts with diseased (3.57±1.40 versus 2.50±0.81; P <0.0001) or unobstructed LMCA (3.40±0.78 versus 2.47±0.68; P <0.0001). Microvascular resistance reserve in the LAD territory was similar regardless of whether the LMCA was obstructed or not ( P =0.56). Similarly, microvascular resistance reserve in the LCx territory was comparable between cohorts ( P =0.88). CONCLUSIONS: Microvascular resistance in the LAD is lower than in the LCx territory. Consequently, fractional flow reserve and nonhyperemic pressure-derived indices are lower in the LAD than the LCx. These findings have important implications for how LMCA atheroma should be assessed in clinical practice and also suggest the need for territory-specific thresholds for defining abnormal microvascular function and epicardial conductance.